Top

CardioVascular and Interventional Radiology

Published in:

01-10-2011 | Clinical Investigation

Changes in Normal Liver and Spleen Volume after Radioembolization with ⁹⁰Y-Resin Microspheres in Metastatic Breast Cancer Patients: Findings and Clinical Significance

Authors: Philipp M. Paprottka, G. P. Schmidt, C. G. Trumm, R. T. Hoffmann, M. F. Reiser, T. F. Jakobs

Published in: CardioVascular and Interventional Radiology | Issue 5/2011

Abstract

Purpose

In clinical trials with yttrium-90-resin-microspheres for the management of colorectal cancer liver metastases, it was observed that radioembolization might result in splenomegaly and an increase in portal vein size. Subclinical hepatitis in normal liver tissue as well as the effects of radioembolization and prior chemotherapy are suspected to be responsible for this phenomenon. The purpose of this study was to quantify the changes in liver and spleen volume and portal vein diameter after radioembolization.

Methods

Twenty-seven patients with liver-dominant metastatic disease from breast cancer who had not responded to chemotherapy or had to abandon chemotherapy because of its toxic effects were evaluated. Changes in liver and spleen volume and portal vein diameter as well as liver tumor volume and diameter were quantified using computed tomography scans.

Results

Radioembolization was associated with a significant mean decrease in the whole liver volume of 10.2% (median 16.7%; P = 0.0024), mainly caused by a reduction in the right lobe volume (mean 16.0%; P < 0.0001). These changes were accompanied by a significant increase in the diameter of the main portal vein (mean 6.8%; P < 0.0001) as well as splenic volume (mean 50.4%; P < 0.0001). Liver-tumor volume and diameter decreased by a median of 24 and 39.7%.

Conclusions

Radioembolization is an effective treatment for tumor size reduction in patients with breast cancer liver metastases. Treatment is associated with changes of hepatic parenchymal volume, splenic volume, and portal vein size that appear not to represent clinically important sequelae in this patient cohort.

Angitapalli R, Litwin AM, Kumar PR et al (2009) Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology 76(5):363–368PubMedCrossRef

Atalay G, Biganzoli L, Renard F et al (2003) Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 39(17):2439–2449PubMedCrossRef

Ayav A, Habib N, Jiao LR (2005) Portal hypertension secondary to ⁹⁰Yttrium microspheres: an unknown complication. J Clin Oncol 23(32):8275–8276PubMedCrossRef

Bangash AK, Atassi B, Kaklamani V et al (2007) ⁹⁰Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 18(5):621–628PubMedCrossRef

Berstein LM, Kovalevskij AY, Poroshina TE et al (2007) Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: role of menopausal status, estrogens and hyperglycemia. Int J Cancer 121(3):514–519PubMedCrossRef

Burstein HJ, Keshaviah A, Baron AD et al (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110(5):965–972PubMedCrossRef

Campbell AM, Bailey IH, Burton MA (2000) Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 45(4):1023–1033PubMedCrossRef

Campbell AM, Bailey IH, Burton MA (2001) Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 46(2):487–498PubMedCrossRef

Chia SK, Speers CH, D’Yachkova Y et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110(5):973–979PubMedCrossRef

10.

Coldwell DM, Kennedy AS, Nutting CW (2007) Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 69(3):800–804PubMedCrossRef

11.

Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103(3):324–331PubMedCrossRef

12.

Dawson LA, McGinn CJ, Normolle D et al (2000) Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18(11):2210–2218PubMed

13.

Eichbaum MH, Kaltwasser M, Bruckner T, de Rossi TM, Schneeweiss A, Sohn C (2006) Prognostic factors for patients with liver metastases from breast cancer. Breast Cancer Res Treat 96(1):53–62PubMedCrossRef

14.

Er O, Frye DK, Kau SW et al (2008) Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 14(1):62–68PubMedCrossRef

15.

Gaba RC, Riaz A, Lewandowski RJ et al (2010) Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction. J Vasc Interv Radiol 21(8):1213–1218PubMedCrossRef

16.

Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104(8):1742–1750PubMedCrossRef

17.

Gulec SA HR, Pennington K et al (2008) A Phase II clinical trial of yttrium-90 microspheres selective internal radiation treatment with concomitant chemotherapy as a front-line treatment in patients with colorectal cancer liver metastases: evaluation of objective tumor response by quantitative FDG-PET/CT imaging. In: Abstract presented at the Society of Surgical Oncology 61st annual cancer symposium, Chicago

18.

Gulec SA, Pennington K, Hall M, Fong Y (2009) Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol 7:6PubMedCrossRef

19.

Ingold JA, Reed GB, Kaplan HS, Bagshaw MA (1965) Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 93:200–208PubMed

20.

Jakobs TF, Hoffmann RT, Fischer T et al (2008) Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 19(5):683–690PubMedCrossRef

21.

Jakobs TF, Saleem S, Atassi B et al (2008) Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with ⁹⁰yttrium microspheres. Dig Dis Sci 53(9):2556–2563PubMedCrossRef

22.

Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C (2004) Pathologic response and microdosimetry of ⁹⁰Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60(5):1552–1563PubMedCrossRef

23.

Kennedy AS, Coldwell D, Nutting C et al (2006) Resin ⁹⁰Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65(2):412–425PubMedCrossRef

24.

Kennedy A, Nag S, Salem R et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68(1):13–23PubMedCrossRef

25.

Kulik LM, Atassi B, van Holsbeeck L et al (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94(7):572–586PubMedCrossRef

26.

Lau WY, Ho S, Leung TW et al (1998) Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of ⁹⁰yttrium microspheres. Int J Radiat Oncol Biol Phys 40(3):583–592PubMedCrossRef

27.

Lim L, Gibbs P, Yip D et al (2005) A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer 5:132PubMedCrossRef

28.

Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z, Atassi B, Barrett K, Gowland P, Oman B, Lewandowski RJ, Gates VL, Thurston KG, Wong CY (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16(7):911–935PubMedCrossRef

29.

Macdonald JS (1999) Adjuvant therapy of colon cancer. CA Cancer J Clin 49(4):202–219PubMedCrossRef

30.

Marn CS, Andrews JC, Francis IR, Hollett MD, Walker SC, Ensminger WD (1993) Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings. Radiology 187(1):125–128PubMed

31.

Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23(19):4265–4274PubMedCrossRef

32.

Moroz P, Anderson JE, Van Hazel G, Gray BN (2001) Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol 78(4):248–252PubMedCrossRef

33.

Morris-Stiff G, Tan YM, Vauthey JN (2008) Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol 34(6):609–614PubMedCrossRef

34.

Murata Y, Ogawa Y, Saibara T et al (2000) Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7(6):1299–1304PubMed

35.

Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, Ahrar K, Wallace MJ, Cohen A, Coldwell DM, Kennedy AS, Hicks ME (2005) Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25(Suppl 1):S41–55PubMedCrossRef

36.

Nalesnik MA, Federle M, Buck D, Fontes P, Carr BI (2009) Hepatobiliary effects of ⁹⁰yttrium microsphere therapy for unresectable hepatocellular carcinoma. Hum Pathol 40(1):125–134PubMedCrossRef

37.

Pentheroudakis G, Fountzilas G, Bafaloukos D et al (2006) Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat 97(3):237–244PubMedCrossRef

38.

Phillips R, Karnofsky DA, Hamilton LD, Nickson JJ (1954) Roentgen therapy of hepatic metastases. Am J Roentgenol Radium Ther Nucl Med 71(5):826–834PubMed

39.

Qayyum A, Lee GK, Yeh BM, Allen JN, Venook AP, Coakley FV (2007) Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Clin Imaging 31(1):6–10PubMedCrossRef

40.

Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15(3):460–466PubMedCrossRef

41.

Sharma RA, Van Hazel GA, Morgan B et al (2007) Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25(9):1099–1106PubMedCrossRef

42.

Stubbs RS (2006) Portal hypertension and liver surgery following selective internal radiation therapy with ⁹⁰Yttrium microspheres. J Clin Oncol 24(9):e15PubMedCrossRef

43.

Stubbs RS, Wickremesekera SK (2004) Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases. HPB (Oxford) 6(3):133–139CrossRef

44.

Tehranipour N, AL-N A, Canelo R et al (2007) Concordant F-18 FDG PET and Y-90 Bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: confirmation with histopathology. Clin Nucl Med 32(5):371–374PubMedCrossRef

45.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRef

46.

Van den Eynde M, Flamen P, El Nakadi I et al (2008) Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med 33(10):697–699PubMedCrossRef

47.

Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065–2072PubMedCrossRef

48.

Wharton JT, Delclos L, Gallager S, Smith JP (1973) Radiation hepatitis induced by abdominal irradiation with the cobalt 60 moving strip technique. Am J Roentgenol Radium Ther Nucl Med 117(1):73–80PubMed

49.

Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94(3):274–286PubMedCrossRef

Title: Changes in Normal Liver and Spleen Volume after Radioembolization with 90Y-Resin Microspheres in Metastatic Breast Cancer Patients: Findings and Clinical Significance
Authors: Philipp M. Paprottka
G. P. Schmidt
C. G. Trumm
R. T. Hoffmann
M. F. Reiser
T. F. Jakobs
Publication date: 01-10-2011
Publisher: Springer-Verlag
Published in: CardioVascular and Interventional Radiology / Issue 5/2011
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-011-0217-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Changes in Normal Liver and Spleen Volume after Radioembolization with ⁹⁰Y-Resin Microspheres in Metastatic Breast Cancer Patients: Findings and Clinical Significance

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2011

Pulmonary Embolism After Uterine Fibroid Embolization: A Case Report

Results of a Seven-Year, Single-Centre Experience of the Long-Term Outcomes of Bovine Ureter Grafts Used as Novel Conduits for Haemodialysis Fistulas

Voice Matters: Late Presentation of an Iatrogenic Vertebral Arteriovenous Fistula after Liver Transplantation in Early Childhood with Successful Endovascular Treatment

Enhanced Ablation of High Intensity Focused Ultrasound with Microbubbles: An Experimental Study on Rabbit Hepatic VX2 Tumors

Hepatic Arterial Embolization with Doxorubicin-Loaded Superabsorbent Polymer Microspheres in a Rabbit Liver Tumor Model

Endovascular Aneurysm Repair Using a Reverse Chimney Technique in a Patient With Marfan Syndrome and Contained Ruptured Chronic Type B Dissection